Podcasts about Casali

Today's episode of PR Not BS is going to be a little bit different because I've handed over to Lauren to interview her guest, Richard Tidmarsh!Richard is based in the Chippenham area and runs two businesses – Casali Recruitment and The Chippenham Dog Walker and Pet Care Services.Casali is a generalist recruitment business who works with a number of businesses both locally and UK wide helping them to recruit for jobs including forklift drivers, call centre staff, welders, stewards for sporting events and more!Richard has a sales background of 30 years which he uses to sell jobs to candidates and candidates to jobs and he enjoys it so much that it doesn't feel like a job to him.Lauren and Richard talk about what it's like to work with family as Richard works with his wife in his dog walking business. They set the company up 12 years ago after temporarily fostering a job and missing the interaction on a daily basis.Networking has been vital for both Lauren and Richard so they talk about the meetings that Richard went to before he joined Business Buzz a year ago where he met Lauren for the first time. One thing that Richard shares is that he's noticed how many other groups he has been to where he feels like he is constantly being sold to and he likes that you don't get that at Business Buzz.If you'd like to know more about Richard you can find him on LinkedIn at https://www.linkedin.com/in/richard-tidmarsh-firp-6b305a1 and www.casalirecruitment.co.ukIf you would like to contact me, you can visit my www.Scottmedia.uk or join my free Facebook group here https://www.facebook.com/groups/prtribe

Pascal Praud revient pendant deux heures, sans concession, sur tous les sujets qui font l'actualité. Vous voulez réagir ? Appelez-le 01.80.20.39.21 (numéro non surtaxé) ou rendez-vous sur les réseaux sociaux d'Europe 1 pour livrer votre opinion et débattre sur grandes thématiques développées dans l'émission du jour.Vous voulez réagir ? Appelez-le 01.80.20.39.21 (numéro non surtaxé) ou rendez-vous sur les réseaux sociaux d'Europe 1 pour livrer votre opinion et débattre sur grandes thématiques développées dans l'émission du jour.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Le Royaume-Uni a longtemps été le pays le plus riche du continent mais les derniers chiffres font état d'une pauvreté qui touche 14,25 millions de Britanniques, d'après le ministère du Travail. 4,5 millions d'enfants vivent en situation de pauvreté. Les banques alimentaires se multiplient pour répondre aux besoins et de nombreux logements mal isolés sont insalubres. Comment le pays en est arrivé là ? Parlons-en avec Juliette Démas, Journaliste, correspondante à Londres de Libération et autrice de "Les affamés du Royaume" (Stock, 2025), Catherine Mathieu, économiste à l'OFCE, spécialiste du Royaume-Uni et Clovis Casali, reporter à France 24. 

The Future of Vaccines: An Interview with the Doctor Who Created the First Fully Humanized Immune Systems in Mice Episode 49: https://cmetracker.net/UTHSCSA/Publisher?page=pubOpen#/getCertificate/10097543   Welcome to Pediatrics Now, hosted by Holly Wayment. In this episode, we are honored to have Dr. Paolo Casali from the University of Texas Health Science Center at San Antonio, a distinguished professor with groundbreaking research in immunology. Dr. Casali and his team have developed the first fully humanized immune system in mice, a monumental achievement that could revolutionize medicine for years to come. Dr. Casali explains the detailed process of creating these humanized mice, which involves grafting human hematopoietic stem cells into immunodeficient mice, resulting in a fully functional human immune system. He shares the significance of this breakthrough, including its potential impact on vaccine development, drug testing, and cancer therapies. Through engaging discussions, Dr. Casali highlights the challenges and triumphs of his research journey, offering listeners an inspiring glimpse into the future of medical science. Tune in to understand how these humanized mice can pave the way for better vaccines and targeted therapies, ultimately reducing the need for animal testing and advancing human health. Don't forget to click on the link in this podcast for a free credit that may include CME, MOC, or ethics credit, depending on our topic or podcast. For more information, visit our website at www.pediatricsnowpodcast.com.  

Dr Miguel Casali  I’m Miguel Casali. A Spanish doctor living in Ireland. I am a family doctor by vocation and looking for the best lifestyle to be happy. I came across family medicine which has brought me closer to understanding people and systems. I came across the ketogenic diet which has helped me to stay focused. I came across art which has helped me to express myself and bring out the best in me. I try to know who I am by knowing who I am not.  Now, I am a rural GP in Kerry, looking after my metabolic health and savouring medicine. Explorer in search of truth. Love healthcare. Connecting is my passion. Recruiting and training global healthcare staff. Personalised and precision medicine is the future. Link to Show Notes on Website https://fabulouslyketo.com/podcast/206. Dr Miguel’s Top Tips Don't believe that the changes are as fast as taking medicines – metabolic changes are powerful but slow. Trust people you think are advising you right – don't give up and continue believing. Never blame yourself and never feel guilty about anything you have done. Resources Mentioned Salvador Talon Freshwell App Apple Freshwell App Play Store Connect with Dr Miguel Casali on social media LinkedIn: www.linkedin.com/in/ miguel-casali Website Details: https://www.cseconnect.ie The Fabulously Keto Diet & Lifestyle Journal: A 12-week journal to support new habits – Jackie Fletcher If you have enjoyed listening to this episode – Leave us a review By leaving us a review on your favourite podcast platform, you help us to be found by others. Support Jackie Help Jackie make more episodes by supporting her. If you wish to support her we have various options from one off donations to becoming a Super Fabulously Keto Podcast Supporter with coaching and support. Check out this page for lots of different ways to support the podcast. https://fabulouslyketo.com/support Or You can find us on Patreon: https://www.patreon. com/FabulouslyKeto Connect with us on social media https://www.facebook.com/FabulouslyKeto https://www.instagram.com/FabulouslyKeto1 https://twitter.com/FabulouslyKeto Facebook Group: https://www.facebook.com/groups/FabulouslyKeto Music by Bob Collum Recommend a guest We would love to know if you have a favourite guest you would like us to interview. Let us know who you would like to hear of if you have a particular topic you would like us to cover. https://fabulouslyketo.com/recommend-a-guest We sometimes get a small commission on some of the links, this goes towards the costs of producing the podcast.

Au Royaume-Uni, les bureaux de vote ont ouvert ce jeudi matin pour des législatives anticipées, qui laissent augurer la fin de quatorze années tumultueuses de règne conservateur, au profit d'une victoire qui s'annonce historique du Parti travailliste. On en parle avec Nicholas Sowels, maître de conférences à la Sorbonne, Clovis Casali, reporter France 24, Philip Turle, éditorialiste, et Christophe Dansette du service économie de France 24.

On today's DEUCES WILD show, EB covers the GIANTS vs the DODGERS game! The Giants just signed Curt Casali to a 1-year deal last night, what an incredible story! He's perfect for the Giants right now, a great example for the young players.

JCO PO author Dr. Christian Rolfo shares insights into his JCO PO article, “Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment.” Host Dr. Rafeh Naqash and Dr. Rolfo discuss how early liquid biopsy in aNSCLC in parallel with path dx is associated with shorter time to treatment. TRANSCRIPT  Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCOPO articles. I'm your host, Dr. Rafeh Naqash, Social Media Editor for JCO Precision Oncology and Assistant Professor at the Stephenson Cancer Center, University of Oklahoma.   Today we are thrilled to be joined by Dr. Christian Rolfo, Associate Director of Clinical Research at the Center of Thoracic Oncology at the Tisch Cancer Institute at Mount Sinai Health System. He is also the lead author of the JCO Precision Oncology article entitled "Liquid Biopsy of Lung Cancer Before Pathological Diagnosis is Associated with Shorter Time to Treatment."  Our guest's disclosures will be linked in the transcript.  Christian, it's great to have you here. Welcome to our podcast and we are excited to learn about some of the interesting results from your study.  Dr. Christian Rolfo: Thank you very much, Rafeh. It's a pleasure to be here and discuss about liquid biopsy. Dr. Rafeh Naqash: You have a very important role in different liquid biopsy consortiums. This is an initiative that you have been leading and spearheading for quite a while, and it's nice to see that it is becoming something of a phenomenon now on a global scale where liquid biopsies are being implemented more and more in earlier stages, especially. For the sake of our audience, which revolves around academic oncologists, community oncologists, trainees, and patient advocates or patients themselves, could you tell us a little bit about the background of what liquid biopsies are? And currently, how do we utilize them in the management of lung cancer or cancers in general? Dr. Christian Rolfo: Liquid biopsy has been gaining importance over the years. We started to talk about liquid biopsy in 2009 when we started to see some correlations with EGFR mutations. In practicality, what we are doing is the most common or most applicable indication is to go for liquid biopsies from the blood, peripheral blood. So we are doing a blood draw and from there, what we are capturing is the DNA or fragments of DNA that are still in circulation. But the liquid biopsy definition is a little bit more broad and we can apply the concept of a minimally invasive approach to different fluids of the body, including pleural effusion, urine, and including CSF that is another indication, there, we are going to be a little bit more invasive than peripheral blood, but it is also an emerging tool that we will have to find specific indicators. In cancer, we started the history of liquid biopsy in advanced disease with the identification of biomarkers, and then from there, we are moving to other scenarios, including, nowadays, monitoring minimal residual disease and early detection. And that is applicable also for other tumors. Dr. Rafeh Naqash: Thank you, Christian, for that summary. Now, as you've rightly pointed out, we have come to implement liquid biopsies more and more, both in the academic setting and the community setting. And this has definitely led to faster turnaround time in some ways compared to tissue. In this study that you have authored with the help of many other collaborators and Foundation Medicine Flatiron Health data, the goal here, from what I understand, was to look at liquid biopsies that were done before, resulted before the pathological diagnosis. Could you tell us a little bit more about the premise of this study, why you thought about this question and how did you try to implement that idea to get to some of the interesting results that you see here? Dr. Christian Rolfo: Yeah, so what we are seeing generally in lung cancer and also in people with other tumors is that patients are having a journey and that they start seeing different doctors until they get a diagnosis. Generally, after the pathological diagnosis, if you don't have an in-house technology that is doing reflex testing, generally, oncologists need to request for testing and that is taking time. So if we are looking for comprehensive days until a patients are able to get a molecular profiling before we start the treatment is sometimes very long. We are talking, in some cases, about months. So, how we can speed the process, that was the main question. We tried to include liquid biopsy in the staging procedures that we generally were doing when we have a clinical diagnosis of lung cancer. It's either images that we are used to do, PET scans, MRIs, and other assessments, we want to include liquid biopsy there before the biopsy. And that's what we did. We were searching for this specific aim using the Flatiron Health Foundation Medicine electronic health records from 280 centers across the United States. We included a big number of patients in this analysis, more than 1000 patients for the first analysis. Dr. Rafeh Naqash: That's phenomenal that you had real-world data from 200+ centers across the US. Of course, when you have patients on a clinical trial versus patients in the real-world, we all know that there are differences in terms of approaching, overseeing, and managing these individuals. So this data set is an extension of what we could see in the real-world setting.  Could you tell us a little bit about the number of patients that you eventually identified that had liquid biopsies done before pathological diagnosis? I think you have different cohorts here, a group that was before and a group that was after, and you compared several important metrics treatment-wise from what I see. Could you highlight those for our listeners? Dr. Christian Rolfo: Yeah. So we were looking for patients who had a liquid biopsy CGP, comprehensive genomic profiling, ordered within 30 days pre diagnosis and post diagnosis. We focused on 5.2% of patients, which corresponded to 56 patients who ordered a liquid biopsy before diagnosis. The median time was eight days between the order and diagnosis and the range was between 1 to 28 days. And that was compared with 1020 patients who ordered a liquid biopsy after diagnosis. It is important to be clear that both cohorts had a similar stage and ctDNA tumor fraction. We can explain later what tumor fraction is, because it was done in addition with a paper that we just published last week. Liquid biopsy patients were consulted to have this CGP median one day after diagnosis, versus 25 days after for patients who had their diagnosis and their liquid biopsy later on. So, from these patients, the majority of the patients, 43% of LBx-Dx were positive for an National Comprehensive Cancer Network driver, and 32% had ctDNA TF >1% but were driver negative, so that is what we call presumed true negative. From here, maybe I can explain what is tumor fraction and, in general, how we use it.  Dr. Rafeh Naqash: I think that would be great for our listeners. We see this often in more and more liquid biopsy results nowadays, and I've tried to explain it to some of my fellows also. So, it would be nice if you explain for the sake of our listeners what tumor fraction is, what does it mean clinically, can you use it in a certain way, what biological relevance does it have. Dr. Christian Rolfo: So we are analyzing another paper that came out this week in cancer research on the concept of tumor fraction and it's a new definition. So what we are doing with tumor fraction is an algorithmic calculation or mathematical calculation on the amount of DNA of the cells also taking into consideration the math, the quantity of DNA present in the sample. So we are going very low in the sensitivity of this analysis and capturing there the real informative results of the ctDNA of the liquid biopsy. So in practicality, when you see a report that says the threshold that was established in this study was more than 1% or less than 1%, so patients who have a tumor fraction of more than 1%, we can really consider this liquid biopsy informative. And also in this next publication, we compared with tissue. In patients with a tumor fraction of more than 1%, were completely 100% correspondent with what we found in the reflected tumor tissue, the NGS. But what happened in patients with a tumor fraction of less than 1%, we can say that these patients are not informative. So we need to wait for the tissue biopsy result to come in because we were able to recuperate several patients that the liquid biopsy was negative with the tissue biopsy positive. This is an important concept because we are distinguishing not only the informativeness of liquid biopsy, but also we can distinguish between patients who are considered not shedder based on what is considered a shedder. And that was a problem until this kind of introduction was a problem before with the technology because the technology wasn't very fast to distinguish the sensitivity or high sensitivity. Now, the sensitivity is no longer a problem. Maybe, there is really value of information in what we have in liquid biopsy, and using this mathematical help, we can get these patients distinguished and help more people. So that would be really interesting. Dr. Rafeh Naqash: You touched on a few important concepts here, and one question I have, and I think there's no better person to answer this question. You're the right person to answer this question for our audience. Do you think when you have a liquid biopsy tumor fraction of less than 1%, and you have a tissue that is pending with an NGS, where tissue NGS has not resulted yet, but liquid biopsy results come in and tumor fraction is less than 1%. But let's say you have a non-smoker with a typical driver mutation and clinical characteristic positive individual in the clinic, and the tumor fraction is less than 1%. How much can you trust that liquid biopsy when the tumor fraction is less than 1%. Because do you think some of these driver mutations, like you mentioned, could be low shedders and you could miss a potentially actionable mutation on a liquid biopsy if the tumor fraction is less than 1%? Is that something that you've looked at or correlated or understood what would be the clinical meaning of that? Dr. Christian Rolfo: Absolutely. So there are two concepts here. A liquid biopsy could be non-informative, and that is what we saw in this paper. So you have patients that have a liquid biopsy negative, and that we see in the clinic, a liquid biopsy negative tissue biopsy positive. That could be because the liquid biopsy is not informative, but it could be also that the patient, for some biological reason, and we don't have an answer about that, they are not shedding the ctDNA in the bloodstream, ctDNA that we can capture. What we saw in different studies, including one of the papers that we presented also in ASCO last year with a MET amplification and  METex14, for example. In the study that was the VISION study using tepotinib, you see that patients who have a liquid biopsy negative are doing a better outcome compared to a patient who have a liquid biopsy positive. So I believe that we still have patients who are not shedders for some biological reason, that could be put in together with patients who have more bone metastasis than organ metastasis, or patients who have more in location, for example in the brain. These patients are difficult to capture in ctDNA due to some biological reasons. But also you have patients who are non-shedders. For the technicality of the parts of this tumor fraction analysis, it is really important to distinguish that and we will hear more and more. So, as you say, we have already some reports in some companies like Foundation are doing, but some others like to incorporate this tumor fraction. And several in-house technologies allow also to have this kind of mathematical calculation. So that is what we are facing now, to really understand better the power of liquid biopsy. Dr. Rafeh Naqash: Now, some of the other things that your project or paper that you published with JCO PO does not necessarily cover is the payer aspect of this. Now, we've had more and more discussions, obviously, and more and more information has been highlighted with the payers that this is an important test and needs to be reimbursed, even though if you do tissue NGS, liquid biopsies are complementary to tissue. So taking both together is probably a better view of the overall tumor or the mutational status of the tumor. But one of the biggest holes in this whole process, and this is my personal experience, I want to know what you think, is that we can't order these tests when the patient is admitted to the hospital, and 50% or more patients end up getting diagnosed in the hospital during an inpatient stay. The average hospitalization for someone with lung cancer is five to seven days on average, and then another one to two weeks to get into the clinic to see an oncologist. So what would your thoughts be there? How can we improve things there in terms of, can we try to do something different so that the payers agree that, yes, you can send a liquid biopsy when the patient is admitted, because there's that 14-day Medicare rule? Has your team, or have you in particular, tried to navigate some of those issues, and what are your thoughts on how we can try to improve some of those conversations?  Dr. Christian Rolfo: Yeah, that's a really good question, because here we are talking about inequities in access to the technology and the results and it's crucial. Several of our patients, specifically in lung cancer, they are coming to our consultations or to the emergency with a very bad situation so they need to be admitted immediately. And as you say, they can be there for one month waiting for results or for recovery or for stabilization of their general condition before we can start. Several of these patients will have some biomarkers that we can target with treatment. So in other words, I will say that this is a stupid rule because we cannot have in 2024 these kinds of limitations to access to treatment when we have on one side, the FDA is doing a terrific job to get drugs approved in a very short time, and on the other side we have payers who are not understanding the concept of molecular or precision oncology.  So what we are trying to do in these cases, to be honest, is to navigate with the vendors and try to get this done. I generally send the samples because I consider that personally that it is a very crucial information. And in several cases, we have started targeted therapies while the patient is still admitted. So I think it's something that we need to put in a better effort, because already we are not doing enough for our patients, if you look at the data of the MYLUNG Consortium that was presented in ASCO some years ago on the testing performance in the community practice, 50% of the patients with lung cancer were tested there were only some in minority groups, African Americans, 39%. So I think we need to do better in education, but also from the payer side, it's really crucial that they understand this concept.  Advocacy groups have a lot of say here. They are also doing an important job on that. We are now launching with ISLC, ISLB, Lung Cancer Europe, and Longevity in a survey that is to make also the patients aware what is the importance of molecular profiling, tissue or liquid biopsy, it's very important that you get something to treat the patient and select the right treatment. And even to say, there'll be a whole other work in your case so that is really important.  Dr. Rafeh Naqash: Absolutely, I completely agree. We have made a lot of strides, but there is still a lot of room for improvement in terms of equity, access, and reimbursement.   Now, one of the things that I noticed in your paper, and you could tell me a little bit more about this, when you looked at the pre-diagnosed liquid biopsies, meaning before tissue diagnosis, 56 individuals there suspected to have lung cancer, community-based testing was identified in 53 individuals versus academic being three. This is very encouraging when you see something like this happening in the community. Did you look at that? Did you try to understand why or how that was the case? Because in a general community setting, I would think that community practices have a more complicated system of reimbursement because they are dependent on direct reimbursement, whereas in bigger academic centers, there's some leeway here and there. So did you try to understand how they were able to order this before tissue, could you give us some insights there? Dr. Christian Rolfo: Yes, I think it was not big in this specific question, but it's a very interesting topic. Because we, generally, in academia, will believe that we are doing the things in advance and we are more, compared with the practical and the general practitioners or the general colleagues in the community practice, we have more resources. But sometimes, and it's true, obviously, we have more resources in terms of research and more opportunities in terms of clinical trials in some cases. But I think we understood with this minimal example that there is an important interest among general oncologists in the community practice to get this done. And this is something we need to emphasize, because sometimes we are putting the blame on our colleagues that are outside the academic centers on this lack of testing, and it's not really true sometimes. So this is a good point to start to work together and try to get more things done for our patients and try to get also the reality.   I think one of the problems we will have in the future that we can face right now is the lack of new figures in this molecular profiling. I am referring, for example, molecular nurses or personnel that is working and helping to get this done. We need to have more people that are working in this education for the patients in the access to treatment and access to the technology, but also to navigate better these problems with payers that sometimes in some patients that seem to be overwhelming. Because when you talk about the $100 that could be extra, it's hard for some patients. So we need to be very conscious about that. So having a new figure in the hospitals and the community practices could help to test more patients.  Dr. Rafeh Naqash: And I think at the end of the day, the payers or the reimbursement mechanisms need to understand that genomics is part of the diagnosis these days. It's not ancillary, it's not an addition, but it is part of the diagnosis. I'm pretty sure you have had similar instances where you get a confusing pathology result but then a genomic result points in a certain direction. You treat the patient in that direction, and then you see the patient benefiting in the tumor shrinking, which suggests that genomics is complementary to the path diagnosis. It's not necessarily a surrogate.You can't replace pathological diagnosis, but you can use genomics as a complementary diagnosis as part of the whole paradigm of treating the entire patient. So I think we definitely need more and more conversations like the ones that you're having or your liquid biopsy consortium is having and then more education from the FDA. Of course, more legislation, more advocacy.   Going back to the paper, I did notice another interesting thing, which is, again, very encouraging is patients with lung cancer with a performance status of 2 or about had a decent proportion of testing done. Which, again, points out to the important concept of avoiding these preconceived biases that, “Hey. If somebody is not a great performance status, testing and finding something in that individual could potentially change a lot for the individual.” Do you have any personal examples from patients you have treated or seen in the clinic for our listeners where you identified something and maybe they were not doing as great initially, and then you identified something in liquid biopsy, treated them and it changed the entire course of their illness and whole trajectory for them? Dr. Christian Rolfo: Being working in lung cancer for years, everyone has this kind of patient that we see that their performance state was very bad. Obviously, as a clinician, we need to identify why the performance is bad and is deteriorating. So we see some patients in lung cancer, some of them, they can have a very important comorbidity packet that is associated with lung cancer. So in patients who have a deterioration for lung cancer, and we find a driver help in some patients that were doing a kind of a weakness, and that is something that we see in several patients, specifically in patients living with leptomeningeal disease. In some cases, when we start to do drivers that have a big impact in the crossing the blood-brain barrier, I have a good response.  I have patients that had an important recovery. So this is something we need to distinguish and sometimes when the patients seem very bad they say, “Okay, we go directly to targeted care or supportive care.” We try to test these patients as well because these patients have an important impact on the quality of life that we are treating. We will not be able to cure patients in this setting with targeted therapies, but we can certainly make an impact in the quality of life and also in our form of survival.  Dr. Rafeh Naqash: One of the other questions that comes up often when you're in a multi display team, since most cancers these days are on the multi display decision making opportunities to treat the patient the best possible way is: Who orders the liquid biopsy? I remember from my fellowship several years back, our program director Paul Walker, who is, again, an amazing lung cancer thoracic oncologist, he had advocated that our endoscopic suite folks, the bronchoscopist, whether it was pulmonary, interventional pulmonology or CT surgeons, whoever did the bronchoscopy for the first time in the patient that they would send it whenever they see the patient from the bronchs. This was around six, seven years back. And I think Paul was a little ahead of his time and I didn't necessarily understand the implications that this would have.  And now, as I progress in my own little career, I can see the vision that he had, which I think a lot of other sectors have tried to do, and I'm pretty sure you have a certain process, too. Is that something we should try to talk more and more about? Because, of course, when you do the bronch, then you get a diagnosis and the patient sees the oncologist. This whole process takes anywhere from two to three weeks, maybe even more for smaller centers. So, is that something that you're doing or you see that you're having more conversations that, “Hey. Whoever sees the patient first should be able to order the liquid biopsy.” It's not necessarily the medical oncologists, it doesn't mean I love to order sequencing results or  sequential tests, but it could cause a delay in the patient care. So, could you tell us a little bit more of that?  Dr. Christian Rolfo: So it's really important, this part, because we need to create in our institution flows that will have this very well organized. And ideally, in the ideal world will be that we have reflex tests coming from the pathologist, but it's not happened in several places, because we don't have our NGS at home, or we are sending to vendors, and sometimes we are not sending to them. So that is one of the aspects.  The second aspect, and that I think is still a problem in some treatment, is that we still have 24:30 cytologists coming out in place of covariances. And in our institution, we were working very hard with our interventional pulmonologists and interventional radiologists to get this quality of tissue appropriate, and we have a very good rate of success and issues in a very minimal quantity of patients. Obviously, some patients are very difficult to get samples, and we need to refer still with cytology. But in some cases, where our surgeons or our pulmonologists have sent in samples for NGS, and I think this is we are coordinating. “I will see this patient next week. Can you please start to order?” And here, our nurse practitioner, our nurses in the team are also playing an important role for the reason I insist in the idea to have new figures that could be these molecular navigators we can call, or molecular nurses that helping coordinate this, not only the coordination, but also in the discussion of molecular tumor boards. We did an experience like that some years ago at Maryland University, and actually it was a very important opportunity to decrease the number of quantities of issues and get the results done very quickly. So I think it's important to come to have conversations with our colleagues, pulmonologists, radiation radiologists, interventional radiologists, pulmonologists and pathologists to get this done very quickly.  Dr. Rafeh Naqash: I love the idea of molecular navigators. And of course, everybody in the current day and age, we're having staffing issues, so getting a molecular navigator would be awesome, but I'm not necessarily sure how everybody would be able to implement it. But I think in the bigger picture, whether it's molecular navigators or multi disciplinary nurse navigators in general, liaisons in general, I think we all can do a better job in trying to coordinate some of these testings. And we have tried to do that through our thoracic oncology group and of course, there's a lot of progress that needs to be made, one step at a time. Dr. Christian Rolfo: If somebody is interested in this topic on the International Society of Liquid Biopsy, we started with a project that is called a Certificate for Advanced Studies in Precision Oncology. So we are educating the healthcare team for all this process and trying to get practical insights to have this career later. Because I think it will be something that's interesting for nurses or pharmacists to get this kind of career later or get another approach in their career.  Dr. Rafeh Naqash: Thank you so much, Christian.  Now, going to not the scientific part, which I think is the most interesting part of this conversation is to talk about you and your personal journey. Could you tell us a little bit about where you started, what your career has been like, how did you progress? Because you have a lot of junior faculty that listen to this and it's always good to take inspiration from people like yourself.  Dr. Christian Rolfo: Thank you. As you can hear my accent, it's not from here. So I was born in Argentina, I did my medical degree there. And then I had the opportunity to get a scholarship in Italy. I went to Italy and I stayed there for seven years. I did my fellowship there again, and I started to know there precision oncologists. My journey started in sarcoma. And actually I was working in the group of Dr. Casali's group, a very well known sarcoma expert. And at that time we were running phase I trials for imatinib, I remember, known as GIST. I saw this kind of response and awakening of patients that were really in very bad condition, with only through this imatinib. Very little to treat that disease at that moment, a median overall survival of two months. So I started to be interested in that. Then I moved from there to Spain and met Dr. Rafael Rossell, who was my mentor. In Italy, I have also a mentor in breast cancer, Dr. Luca Gianni, one of the pioneers in breast cancer treatment. So knowing all these people and having the support of them, was really crucial.  So I think this is the first advice for junior faculty: try to choose your mentor, even if your mentor is not in your center. Like the case, for example, Rafael Rossell was not in my hospital, but he was my mentor. So having this kind of discussion, I did my PhD in EGFR mutation, at that time was the fashion, not immunotherapy, of the moment. And then from there, after eight years in Spain, I moved to Belgium. I have a short period of completing my training at MD Anderson and I went to Belgium to Antwerp University and that was the opportunity to become the Director of the phase I program in the Early Clinical Trials Unit. It was really exciting to see growing a unit, and now they continue  at the center in Belgium. My colleagues that stayed there, they are doing a terrific job of continuing this idea. And from there I went to Baltimore, three years working at Maryland University being the Director of Thoracic Oncology and early clinical trials as well. Three years after, I moved to New York, and here doing this journey in clinical research, also being the Director of Clinical Research at the Center for Thoracic Oncology.  Life has put me in different places, different cultures, different opportunities. For me it was a really good journey to be in different countries, knowing different ways to see oncology as well, and immediately to work, because it was a shock coming from Belgium to the area of Baltimore where I had the reality to discuss peer to peer conversations and things that are not usually discussed in Europe. So it was really a very nice journey to learn, to have the capacity to adapt.  That is the other thing, my second advice, if I can give advice, but if you have the opportunity to go to some place, adaptation is the most important. So try to enjoy what you're doing and try to enjoy and learn from the patients, hopefully, and contribute your knowledge as well. Dr. Rafeh Naqash: Thank you so much, Christian. Two last questions. For all the places that you visited, what is your favorite place? And what is your favorite food? Dr. Christian Rolfo: My favorite place to live, I have Italy in my heart. Obviously, Argentina is my place, family. But Italy is in my heart. And then Spain, Spain gave me my wife and my son. So I have very good memories there and it's a very nice place. Obviously, I'm Argentinian, so for me it means meat in some places, Asado, that is a typical Argentinean one. But also, I am very eager to enjoy the pasta and paella, so we have several things. Anyway, here in New York, the pizza of New York is great. It is not Italian. This new way to make pizza from New York is fantastic.  Dr. Rafeh Naqash: I can try to see you're trying to keep everybody happy in a politically correct way. Dr. Christian Rolfo: I didn't mention Belgium, but we have chocolates there.  Dr. Rafeh Naqash: That is true. Every place is special and unique in different ways.  Christian, thank you so much. This was very entertaining and very informative for me and hopefully for the audience. Thank you so much for being a part of this conversation. And thank you so much for submitting your work to JCO PO. We hope you consider JCO PO for future research in this exciting area as well.  Dr. Christian Rolfo: Thank you. Thank you very much, Rafeh, for the opportunity. And JCO Precision Oncology is a really great forum to discuss precision medicine. Congratulations for all your work. The last, if you allow me to give an advertisement here. We have our Liquid Biopsy Congress, the ISLB, the annual conference will be in Denver from 20 to 25 November, so just before Thanksgiving day. So if you are able to go there, we will have a lot of discussion on liquid biopsy like we did today. Thank you very much.  Dr. Rafeh Naqash: Thank you so much for highlighting that, and hopefully, our listeners will try to register and be part of that meeting.  Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review. And be sure to subscribe so you never miss an episode. You can find all our shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Cet épisode vous est proposé gratuitement en partenariat avec ISpeakSpokeSpoken.com la plus grande communauté d'apprentissage de l'anglais en France sponsorise cet épisode. Recevez gratuitement votre challenge PDF pour vous (re)mettre à l'anglais en 4 semaines en suivant le lien créé pour vous : www.ispeakspokespoken.com/timeline Pour vous abonner à nos 300 émissions hebdomadaires d'une heure sans publicité pour seulement 2€ par mois, avec une nouvelle émission chaque jeudi rien de plus simple, cliquez ici : https://m.audiomeans.fr/s/S-tavkjvmo Notre Histoire est accusée d'être à l'origine de tous les maux de notre société actuelle. La dégradation des statues de personnalités historiques, telles celles de Colbert ou de Napoléon, est devenue une pratique courante. Ce phénomène, appelé cancel culture, culture de l'effacement, nous vient des États-Unis. Dimitri Casali pointe une fracture qui ne cesse de diviser notre belle Nation, au risque de la voir s'effondrer. Son histoire est notre dernier recours pour cesser de déconstruire et reconstruire notre patrimoine et notre cohésion sociale. Effacer notre passé, ce serait renier ce qui fait l'âme française. Avec ces statues que l'on abat, c'est nous que nous abattons. Les préserver, c'est nous sauver ! Dimitri Casali est notre invité pour Xpresso, dans le cadre du Salon du Livre d'Histoire de Versailles

Pedro Casali veio contar para nós sobre seu livro, fazer aquelas piadas totalmente sem limites e claro, fazer o Bola chorar de rir!

Juliana hizo una fuerte confesión en el programa que nadie esperaba, así como nadie esperaba la reunión entre Petro y Bill Gates para hablar de The Walking Dit. Bienvenidos a este Gallo Pódcast.

New York-based shiitake mushroom chip company Popadelics is on a mission to bring attention to under-loved vegetables. In this episode, George Hajjar, associate editor at the SFA, speaks with co-founders and life partners Marilyn Yang and Michael Casali about transitioning to the food world from a finance background, the origins of the pandemic-born snack, and their recent success, particularly in alternate channels including Urban Outfitters. Additionally, Yang highlights some of the brand's philanthropic achievements, including its partnership with the Johns Hopkins Center for Psychedelic & Consciousness Research.Spill & Dish is Powered by Simplecast.

Originally aired May 7, 2018On today's show, Amber Casali joins Curt to fill us in on everything we didn't realize we did not know about fire lookout towers. Born and raised in Seattle, Amber Casali considers herself a stereotypical Pacific Northwesterner, someone who loves the outdoors and relishes the natural beauty of our region. She has summited Mount Adams, Mount Baker, and Mount Rainier; section hiked most of Washington's PCT, including six days solo in Glacier Peak Wilderness; successfully taken the Washington Alpine Club's Basic Climbing and Mountaineering course; and she has recently become certified in Wilderness First Aid, through NOLS. Stay tuned. This show has some really interesting information you don't want to miss!Book: "Hiking Washington Fire Lookouts"www.ambercasali.comwww.mountaineers.org/books/books/hiking-washingtons-fire-lookoutsOur Sponsors:* Check out Green Chef and use my code asp250 for a great deal: https://www.greenchef.com/asp250* Check out Oris Watches: https://www.oris.ch* Check out Roark and use my code ASP15 for a great deal: https://roark.com/* Check out Shopify and use my code asp for a great deal: https://www.shopify.com/aspSupport this podcast at — https://redcircle.com/adventure-sports-podcast/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

C dans l'air invité du 22 novembre 2023 - Dimitri Casali, essayiste, historien, spécialiste de Napoléon, auteur de “Ces statues que l'on abat” Ridley Scott est de retour au cinéma aujourd'hui avec un 28e long métrage : "Napoléon", interprété par Joaquin Phoenix. Le film est déjà sous le feu des critiques. Pour Le Figaro, c'est "Barbie et Ken sous l'Empire", "un tout petit empereur" pour l'hebdo Marianne, un film "pompier, grandiose, mais qui s'autodégrade sur la longueur" pour France Culture, et de son côté, Le Point pointe une interprétation antifrançaise et probritannique. Des historiens français et anglais ont reproché au "Napoléon" de Ridley Scott de véhiculer une image négative de l'Empereur avec une multitude d'erreurs historiques. A la BBC, Ridley Scott s'est défendu en affirmant que "les Français ne s'aiment pas eux-mêmes !". Dimitri Casali, historien et spécialiste de Napoléon le rejoint sur ce point et se réjouit que ce film fasse rayonner Napoléon à l'international. Selon lui, "le problème majeur est qu'il n'y ait pas de films sur Napoléon en France". "Il est dans notre soft-power, et ce sont les étrangers qui font un film sur lui". Dimitri Casali est essayiste, historien, spécialiste de Napoléon. Il a publié "Ces statues que l'on abat", aux éditions Plon, dans lequel il revient sur la dégradation des statues de personnalités historiques depuis l'apparition du mouvement de la cancel culture. Il reviendra sur le mythe mondial qu'est Napoléon et sur l'adaptation de l'Empereur réalisée par Ridley Scott.

The history of music-making in Rome tends to focus on Renaissance polyphony, with an occasional nod to the Baroque thereafter. But thanks to composers like Giovanni Battista Casali (1715–92), choral music continued to flourish in Roman churches and other religious establishments in the eighteenth century, too, until Napoleon's occupation broke many of its traditions. Casali's music, though, is as good as unknown, and this pioneering recording reveals a composer at home in the galant style – with a surprising fondness for the occasional dissonance.Tracks Confitebor tibi, Domine (2:02) Comedetis carnes (2:54) Adiuva nos, Deus (2:18) Improperium expectavit* (2:34) Tantum ergo (3:38) Christum regem adoremus (2:37) Ad te levavi (2:38) Ave Maria a4 (3:38) Exaltabo te (2:50) Hodie nobis de caelo (2:23) Quem vidistis pastores (2:36) Constitues eos (2:13) Ave Maria a8 (4:05) Justus ut palma (2:45) Scapulis suis (3:32) Caro mea, vere est cibus (3:18) Haec dies (2:39) Memoria fecit (Confitebor in D)(2:22) Gloria Patri (Confitebor in D) (3:26) All Except * First RecordingsHelp support our show by purchasing this album  at:Downloads (classicalmusicdiscoveries.store) Classical Music Discoveries is sponsored by Uber. @CMDHedgecock#ClassicalMusicDiscoveries #KeepClassicalMusicAlive#CMDGrandOperaCompanyofVenice #CMDParisPhilharmonicinOrléans#CMDGermanOperaCompanyofBerlin#CMDGrandOperaCompanyofBarcelonaSpain#ClassicalMusicLivesOn#Uber#AppleClassical Please consider supporting our show, thank you!Donate (classicalmusicdiscoveries.store) staff@classicalmusicdiscoveries.com This album is broadcast with the permission of Sean Dacy from Rosebrook Media.

POTERE AL POPOLO – S.VARIN – D.TORRISI – M.CASALI – D.GERBINO – 13 – 06 – 2023

Unternehmensberater Mathias Burtscher zum Thema Gehälter in Vorarlberg, und Tino Casali vom SCR Altach zu Derby und Abstiegskampf sind am Montag zu Gast bei "Vorarlberg LIVE".

3 bars from Austria and Hungary are headed towards the You Tried Dat?? crew's mouths: Sport, Casali Chocolate Bananas, and Bobby.  Which will take home the landlocked central European crown?  They also discuss antics and gymnastics and penguin plays before holding another duos tournament. Follow us on Instagram to see pictures of the snacks @youtrieddat.

Sat, 22 Apr 2023 03:45:00 +0000 https://jungeanleger.podigee.io/754-sportwoche-podcast-s3-08-karin-steinhart-die-managerin-die-stefan-kraft-sara-marita-kramer-und-dawid-kubacki-rosa-macht 25bf6da006feafcc2b6cb7fe6f160aa0 Karin Steinhart ist Leiterin Unternehmenskommunikation & Sponsoring bei Manner, davor sprach sie u.a. für T-Mobile, Ford, Nestle und Unilever. 2010 zu Manner gewechselt übernahm Karin auch das Sponsoring etlicher Skisprungstars aus mehreren Ländern und entwickelte dies laufend weiter. 2022/23 waren Stefan Kraft, Sara-Marita Kramer, Jan Hörl und Daniel Huber (alle A), Karl Geiger und Pius Paschke (D) sowie Dawid Kubacki (POL) sehr rosa unterwegs, dazu gab es rosa Events wie die WM in Planica. Wir reden aber auch über Fussball, Almdudler, die Nachbarn von Ottakringer. ESG und die sehr starke Manner-Aktie an der Wiener Börse. Für die weiteren Manner-Marken wie Casali, Victor Schmidt Mozartkugeln, Ildefonso und Napoli durfte ich Sponsoring-Ideen deponieren. Und nachher gab es einen Plauderlauf mit Karin in rosa, die Plauderlauf-Startfotos sind aber natürlich leider wie immer schwarz-weiss. https://www.manner.com/de-AT https://www.manner.com/de-AT/uber-manner/manner-skisprung-202223 Plauderlauf: https://photaq.com/page/pic/94590/ About: Die Marke, Patent, Rechte und das Archiv der SportWoche wurden 2017 von Christian Drastil Comm. erworben, Mehr unter http://www.sportgeschichte.at . Der neue SportWoche Podcast ist eingebettet in „ Wiener Börse, Sport, Musik (und mehr)“ auf http://www.christian-drastil.com/podcast und erscheint, wie es in Name SportWoche auch drinsteckt, wöchentlich. Bewertungen bei Apple machen mir Freude: https://podcasts.apple.com/at/podcast/audio-cd-at-indie-podcasts-wiener-boerse-sport-musik-und-mehr/id1484919130 . Unter http://www.sportgeschichte.at/sportwochepodcast sieht man alle Folgen, auch nach Hörer:innen-Anzahl gerankt. 754 full

Juliana volvió a un Motel después de mucho tiempo, pero no a lo que ustedes creen, escuche esta triste historia en El Gallo Pódcast mientras sube a la piedra del Peñón que ahora es escenario de videos porno.

The gang discusses two papers that use morphometric studies to investigate patterns of ecomorphy in the fossil record. Specifically, they look at two papers that investigate how morphology in sloths and pterosaurs changes over time, and how well these changes map onto changes in body size and ecological shifts. Meanwhile, Amanda could be dean, Curt has opinions on figures, and James provides butchery advice.   Up-Goer Five (Curt Edition): The friends talk about two papers that look at how things look and how that changes over time, and looks to see if these things are changing because of what they do. The first paper looks at animals with hair and long arms that move very slow. There are not a lot of these animals today, but in the past there was a lot of these animals and they did a lot of other things that we do not see them do today. These animals were also looking different as well. But it seems that the things that look different are closer to each other by being close sisters to each other. They also do find that these animals are also doing different things when they look different. The second paper looks at angry animals who can fly but are not the animals that can fly today. These animals start small and get big over time. They actually get big a few times. This paper looks at the parts of these animals and shows the many different ways that parts can change to make these animals big or small. It also shows that, when these things get really big is when the group seems to be doing really bad.   References: Yu, Yilun, Chi Zhang, and Xing Xu. "Complex macroevolution of pterosaurs." Current Biology 33.4 (2023): 770-779. Casali, Daniel M., et al.  "Morphological disparity and evolutionary rates of cranial and  postcranial characters in sloths (Mammalia, Pilosa, Folivora)." Palaeontology 66.1 (2023): e12639.

Pour vous abonner à nos 300 émissions hebdomadaires d'une heure sans publicité pour seulement 2€ par mois, avec une nouvelle émission chaque jeudi rien de plus simple, cliquez ici : https://m.audiomeans.fr/s/S-tavkjvmo Vous ne le saviez peut-être pas, mais l'histoire de France a fait l'histoire du monde. De la construction de la basilique Saint-Denis, marquant l'invention de l'art français, à l'incendie de Notre-Dame de Paris, ce livre révèle ce que la France a apporté au monde. Qui sait encore, aujourd'hui, que l'art gothique est né en France ? que ce sont des Français qui ont fondé les villes qui allaient devenir Montréal, Detroit, Saint-Louis ou Brazzaville ? que ce sont les Françaises qui furent les pionnières de l'égalité des sexes ? que c'est un médecin français qui a découvert l'origine de la peste, ou que l'Inde a failli devenir française ? De l'âge d'or des cathédrales à l'invention de la laïcité, de l'esprit des Lumières à l'abolition de l'esclavage en passant par l'invention de l'aviation et du cinéma, Dimitri Casali nous fait découvrir ou redécouvrir combien l'histoire de France a inspiré le monde. Dimitri Casali était notre invité sur Xpresso, au Salon du livre d'Histoire de Versailles

Sono ben due gli ospiti del terzo episodio della serie di podcast “Storie di sostenibilità” di Smartfood: Lisa Casali e Franco Aliberti. Lisa è scienziata ambientale, il suo ultimo libro è Il Dilemma del consumatore green. Manuale per acquisti a basso impatto ambientale (Gribaudo). Franco è uno chef, che ama definirsi cuoco antispreco, ha pubblicato con Gribaudo il libro Uno. In cucina con 1 solo ingrediente.Lisa e Franco, intervistati da Francesca Gennaro, nutrizionista del team Smartfood IEO, con le loro scelte di vita e professionali, sono una famiglia molto attiva in tema di antispreco. Scopriremo in questa piacevole chiacchierata le potenzialità degli scarti vegetali e con quali strategie è possibile impiegarli nelle preparazioni dei nostri piatti. Lisa ci spiega come fare scelte più consapevoli nei nostri acquisti, perché siano improntati alla tutela dell'ambiente, e Franco come esaltare gli alimenti che cuciniamo attraverso tecniche di cottura sostenibili.

Hoy felicitamos al Montu por su increíble participación como finalista en Casa Beat!! Revisamos los momentos más icónicos de su presentación y las noticias del día viernes, porque la Acusación contra Giorgio Jackson fue rechazada en la Cámara Baja, al igual que fue rechazada la nulidad solicitada por el ex carabinero Patricio Maturana. Además, recibimos a la dramaturga Rae del Cerro y a la actriz Carla Casali con quien conversamos sobre la obra “Antes de morir quiero conocer el cielo”, que aborda la desaparición y asesinato de una joven lesbiana en una localidad semi-rural de Chile.

Today on the podcast I'm talking to Dario Casali, co-creator of The Plutonia Experiment, contributor to Memento Mori, and one of the early members of Valve, where he has worked on Half Life, Half Life 2, Portal 2, the Left 4 Dead games, Team Fortress 2, Half Life Alyx and many more projects. He also has a Youtube channel where he swears at some of his old maps and also other people's. We talk about the early stages of Plutonia, competition with his brother Milo (whose name I embarrassingly mispronounce at the start of the podcast), moving to Valve and Half Life 1, why Half Life 3 never came out, Dario's favourite game to work on, and the potential of virtual reality with Half Life: Alyx.

Mendocino, Humboldt, and Trinity counties in Northern California make up the Emerald Triangle, an area known for its legacy farms and cultivars that many believe to be the origin of the US cannabis industry. On this episode of Let's be Blunt, Montel talks with a second-generation Craft Cannabis Farmer who served eight years in prison for growing the plant he and his community have depended on for decades. John Casali of Huckleberry Farms shares his family's history with the cannabis plant, his time served for growing it, and what he is doing today in the legal market.Support the showFor More Let's be BLUNT with MontelInstagram https://www.instagram.com/letsbebluntmontel/orYouTube https://www.youtube.com/channel/UCMGyFAMo_k-0Q7Ui9DXCCmQ

Avec Dimitri Casali, écrivain et essayiste spécialisé dans la vulgarisation historique, Auteur de « Histoire de l'armée française - De la guerre de Cent Ans à nos jours » aux éditions Ring Retrouvez Bercoff dans [...]

Une heure d'entretien incontournable en partenariat avec CNEWS et Les Echos. Une personnalité politique, un dirigeant économique ou un intellectuel revient sur les grands thèmes de l'actualité et répond aux questions sans détour de Sonia Mabrouk pour apporter des réponses concrètes aux Français.

Today we're talking to Johnny Casali of Huckleberry Hill farms and hearing about his experiences growing up in Humboldt. Johnny has an incredible story from Family Farmer, to prison, to public advocate, Johnny is a true advocate for craft cannabis.    Huckleberry Hill Farms: https://pickhumboldt.com/  Website: www.bluegrasscannabis.com  Instagram: https://www.instagram.com/bluegrass_cannabis/  Twitter: https://twitter.com/BlueGrassCanna  TikTok: https://www.tiktok.com/@bluegrasscannabis 

We remember and talk about the greatest of all time Vin Scully, his life, legacy and what he meant to both of us as baseball fans hearing him throughout our entire lives. Giants win 4 game series against the cubs but who cares when the Dodgers shit all over your season. Dodgers win series over the Rockies but then beat the Giants like they stole something. At the deadline the Dodgers add Joey Gallo and Chris Martin. Giants lose Ruf, Casali and Boyd for prospects and JD Davis confusing and pissing off the entire fan base. Padres add Juan Soto, Yankees, Braves and Seattle add big. We look forward to next week for the Dodgers and Giants, this and so much more on this week's episode!

Alex Pavlovic and Cole Kuiper break down the Giants' decision to hold on to Carlos Rodón and Joc Pederson, the reasons San Francisco parted ways with Darin Ruf and Curt Casali and where the team stands in the NL West after the Padres made the blockbuster trade for Juan Soto and the Dodgers acquired Joey Gallo.(1:36) Giants keep Rodón, Pederson at deadline(6:09) Ruf headed to Mets in trade(13:09) What does Casali trade mean for Bart?(17:31) Padres acquire Soto from NationalsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What we're talking about today: -Trade deadline passed-Giants makes no BIG moves-Padres get Soto-Giants make minor trades-Giants dwindling attendance-All Star break talk-Dodgers fans are a problem, LOL-Ruf & Casali gone!-A's trade to Yankees-Giants problems overall-49ers Training CampTill next podcast!!! Support the show

Former Giants' GM Bobby Evans joins Guru & Krueger to react to the Juan Soto trade and what the Giants Trade Deadlines of the past could teach us as the 2022 Deadline looms. Also, the Giants finally make some trades involving Darin Ruf heading to the Mets & Curt Casali heading to the Seattle Mariner.

John Casali & Jason Gellman are the Executive producers of the show, Tangled Roots: The true Story of Humboldt County. They continue to innovate while also paying homage to their family and those that kept cannabis thriving in the Emerald Triangle through prohibition. It's never about one of us, it's always about all of us! See omnystudio.com/listener for privacy information.

Wilmer Flores. Evan Longoria. Curt Casali. The San Francsico Giants rode clutch home runs from those three veterans to a resilient 5-4 win in Philadelphia. The offense was sputtering again until Flores' two-run shot tied it. We were still tied in the 9th when Longoria's solo blast gave the SF Giants the lead. And Casali's blast felt the biggest of them all, a two-run bomb that gave the Giants a two-run lead in the 10th. Logan Webb actually allowed three homers himself, but the damage was limited as they were all solo shots. Despite the three home runs allowed, Webb was brilliant in this game. He struck out 10 and walked none. Giants manager Gabe Kapler actually shook Webb's hand and told him he was coming out of the game after the 8th, but Webb talked his way into going back out there. It didn't work out, as Webb immediately allowed a game-tying homer to Kyle Schwarber, but Webb and the team at large appreciated Kapler's willingness to place trust in his young ace pitcher. Dom Leone and Camilo Doval were sharp the rest of the way. Donovan Walton had a particularly rough at-bat in the 10th. He took what should've been ball four, but continued to stand around the plate until the catcher asked if he might've swung. The home plate umpire checked, and the third base umpire said he did. None of that would've happened if Walton had just taken off for first base. He clearly didn't know the count, and it could've easily cost the Giants in a big way. Walton then chased way out of the zone of the next pitch for strike three, failing to advance the free runner placed at second base to begin each extra inning. Thankfully, the next man up Casali lifted a mammoth home run to left that saved the day. Fans have been asking why Walton has been playing over Thairo Estrada, and an explanation is provided on the show. Find and follow Locked On Giants on your favorite podcast platforms:

Wilmer Flores. Evan Longoria. Curt Casali. The San Francsico Giants rode clutch home runs from those three veterans to a resilient 5-4 win in Philadelphia. The offense was sputtering again until Flores' two-run shot tied it. We were still tied in the 9th when Longoria's solo blast gave the SF Giants the lead. And Casali's blast felt the biggest of them all, a two-run bomb that gave the Giants a two-run lead in the 10th.Logan Webb actually allowed three homers himself, but the damage was limited as they were all solo shots. Despite the three home runs allowed, Webb was brilliant in this game. He struck out 10 and walked none. Giants manager Gabe Kapler actually shook Webb's hand and told him he was coming out of the game after the 8th, but Webb talked his way into going back out there. It didn't work out, as Webb immediately allowed a game-tying homer to Kyle Schwarber, but Webb and the team at large appreciated Kapler's willingness to place trust in his young ace pitcher. Dom Leone and Camilo Doval were sharp the rest of the way.Donovan Walton had a particularly rough at-bat in the 10th. He took what should've been ball four, but continued to stand around the plate until the catcher asked if he might've swung. The home plate umpire checked, and the third base umpire said he did. None of that would've happened if Walton had just taken off for first base. He clearly didn't know the count, and it could've easily cost the Giants in a big way. Walton then chased way out of the zone of the next pitch for strike three, failing to advance the free runner placed at second base to begin each extra inning. Thankfully, the next man up Casali lifted a mammoth home run to left that saved the day. Fans have been asking why Walton has been playing over Thairo Estrada, and an explanation is provided on the show.Find and follow Locked On Giants on your favorite podcast platforms:

Former San Francisco Giant and current tv broadcaster for NBC Sports Bay Area, Shawn Estes discusses a weird weekend of Giants baseball as well as the changing dynamic at the catcher position with Casali being the better option right now to win baseball games See omnystudio.com/listener for privacy information.

Former San Francisco Giant and current tv broadcaster for NBC Sports Bay Area, Shawn Estes discusses a weird weekend of Giants baseball as well as the changing dynamic at the catcher position with Casali being the better option right now to win baseball games See omnystudio.com/listener for privacy information.

Well, they did it. The San Francisco Giants made another unpopular option decision, sending hot-hitting outfielder Luis González back to the minor leagues. González didn't deserve to be demoted, but the Giants had virtually no other choice. The only other conceivable option would've been carrying only 12 pitchers, which was clearly something they did not want to do—particularly in Denver.Same thing happened with LaMonte Wade Jr. last year, and he was back up in four days after Brandon Belt got hurt. González very much put himself on the map with his month of strong play in the majors, and rest assured that he will be back. This is his last option year, and the SF Giants can retain his rights for six seasons. If he continues to play well, he could be part of the mix for a long time. Starting next season, he will no longer be able to be optioned.Getting to the actual game, it was the Curt Casali and Mike Yastrzemski show on offense. Those two combined for three home runs, and the Giants needed every last one. Casali slugged two, and SF Giants catchers are now second in the majors in wRC+. Yastrzemski has been strong all season, and his home run last night was an impressive blast to right that traveled 420 feet. The San Francisco Giants' offense is second in the majors in runs scored per game.John Brebbia and Camilo Doval closed it out in the final two frames with scoreless outings. Prior to the game, Mauricio Llovera was added to the roster, Yunior Marte was optioned, and Anthony DeSclafani was placed on the 60-day injured list. DeSclafani isn't eligible to return until June 21.Find and follow Locked On Giants on your favorite podcast platforms:

Well, they did it. The San Francisco Giants made another unpopular option decision, sending hot-hitting outfielder Luis González back to the minor leagues. González didn't deserve to be demoted, but the Giants had virtually no other choice. The only other conceivable option would've been carrying only 12 pitchers, which was clearly something they did not want to do—particularly in Denver. Same thing happened with LaMonte Wade Jr. last year, and he was back up in four days after Brandon Belt got hurt. González very much put himself on the map with his month of strong play in the majors, and rest assured that he will be back. This is his last option year, and the SF Giants can retain his rights for six seasons. If he continues to play well, he could be part of the mix for a long time. Starting next season, he will no longer be able to be optioned. Getting to the actual game, it was the Curt Casali and Mike Yastrzemski show on offense. Those two combined for three home runs, and the Giants needed every last one. Casali slugged two, and SF Giants catchers are now second in the majors in wRC+. Yastrzemski has been strong all season, and his home run last night was an impressive blast to right that traveled 420 feet. The San Francisco Giants' offense is second in the majors in runs scored per game. John Brebbia and Camilo Doval closed it out in the final two frames with scoreless outings. Prior to the game, Mauricio Llovera was added to the roster, Yunior Marte was optioned, and Anthony DeSclafani was placed on the 60-day injured list. DeSclafani isn't eligible to return until June 21. Find and follow Locked On Giants on your favorite podcast platforms:

Dario Casali is a level designer known for his contributions to Final Doom's The Plutonia Experiment, the Half-Life series, Left 4 Dead, & Portal 2, to name only a few. Here he joins Bridgeburner to shed some light on what he's learned in 25 years of designing levels for some of the greatest game franchises of all time. // Dario: https://doomwiki.org/wiki/Dario_Casali (https://doomwiki.org/wiki/Dario_Casali) // Bridgeburner: https://twitter.com/Bridgeburner4 (https://twitter.com/Bridgeburner4) // Hellforge Studios: https://hellforgestudios.com/ (https://hellforgestudios.com/) // In The Keep:https://inthekeep.com/ ( https://inthekeep.com/) //

On today's Locked On Giants podcast, host Ben Kaspick discusses the latest with MLB lockout. Commissioner Rob Manfred met with the media on Thursday and expressed optimism about the league and the players reaching a deal in time to begin the season as planned on March 31. Previously, the league had said it would not make a counteroffer to the players' latest offer, but they have since backed off that position, and they plan to make a core economics proposal on Saturday. Jon Heyman of MLB Network and Audacy Sprots reports that the league is expected to make significant concessions in its next proposal.Manfred also mentioned that the league has "agreed to" a universal DH and the elimination of the qualifying offer. These statements have sparked some confusion; what he meant was that the league has offered those concessions in its rejected proposals. No official agreements have actually been made to this point.Finally, Ben gets into some mailbag questions. He names Joey Bart, Heliot Ramos, Sammy Long, Camilo Doval, Kervin Castro, Gregory Santos, Sean Hjelle, and others as prospects who could play roles for the Giants this season. Speaking of Bart, he also discusses the Giants' catcher situation, which is much worse off after Buster Posey retired. Bart and Casali is not a strong enough pair at this point, and some kind of additional move (or moves) will need to be made prior to the start of the 2022 season.Support Us By Supporting Our Sponsors!Built BarBuilt Bar is a protein bar that tastes like a candy bar. Go to builtbar.com and use promo code “LOCKED15,” and you'll get 15% off your next order. Learn more about your ad choices. Visit podcastchoices.com/adchoices

John Casali of Huckleberry Hill Farms is a Second Generation Cannabis farmer with a long legacy of building community in Humboldt County. John is a passionate pioneer in the legal cannabis space. He continues to innovate while also paying homage to his family and those that kept cannabis thriving in the Emerald Triangle through prohibition. The unique seed lines grown at Huckleberry Hill Farms provide nostalgic trips down memory lane while supporting local farms in the community through unique collaborations like Tangled Roots and opening up to tourism to educate and enlighten the people. We are grateful for John's example and appreciate his insight & story while Huckleberry Hill Farms harvests fresh flagship flowers like Whitethorn Rose for the 2021 Croptober celebrations.

BCBA Rosa Casali has been practicing ABA for 13 years and is the founder of Behavior Solutions Inc. Her firm provides in-home care for families in the Miami area. Rosa has a master's degree in mental health counseling and fell in love with ABA after taking an advanced course in the subject. She knew she wanted to help children and their families and becoming a BCBA was a hands-on way of doing so. Miami is a melting pot of cultures and Rosa's been able to learn from people of all kinds of backgrounds. Different ethnicities approach autism and disabilities differently, which affects how the treatment is approached and progress is made. Some families have a lack of information and resources to help them understand their child's diagnosis. Being able to provide this for clients is something Rosa enjoys. When working with different cultures, take your time to study them, even if it's as simple as doing a quick internet search. Ask the families about what they prefer, especially when entering their home, as they can have varying customs. When you show consideration to families, it builds trust and a lasting relationship. When setting treatment goals, ask the family what they have in mind. Sometimes the plan you initially bring won't be a good fit with their culture or overall plans for their child. When you refrain from putting your agenda on families and let them drive the process, treatment is more successful. When working with culturally diverse families, it helps to ask for feedback. Taking the initiative to make changes so families feel more comfortable is always worth it. For new BCBAs, the best advice would be not to give up. The field can be very challenging, especially when first starting out, but it is an extremely rewarding career.What's Inside:How do different cultures feel about getting a diagnosis for their child and how do they approach treatment.Discussion on different ethnic customs within the home setting.Advice on how to work with culturally diverse clients.Mentioned In This Episode:HowToABA.comHow to ABA on YouTubeFind us on FacebookFollow us on InstagramBehavior Solutions Inc. 

On today's Locked On Giants podcast, host Ben Kaspick hands out Giants midseason awards. The MVP award realistically could have gone to three different Giants. Brandon Crawford, Kevin Gausman, and Buster Posey all had phenomenal first halves, but only one can win! Ben also talks about the Giants' Cy Young, which could go to Gausman, Anthony DeSclafani, Tyler Rogers, or Jake McGee. Most surprising player comes down to LaMonte Wade Jr, Evan Longoria, Steven Duggar, and Curt Casali. Finally, the best and worst moment of the year are considered. The Opening Night loss to the Mariners is up there, as is a stunning loss in Colorado. Among the best moments under consideration are the Mike Tauchman catch in LA, Casali's walk-off against the A's that made the Giants the first team to 50 wins, and Mike Yastrzemski's splash-hit grand slam that completed a comeback from being down 7-0. What a first half it was for the 57-32 Giants.Support Us By Supporting Our Sponsors!Built BarBuilt Bar is a protein bar that tastes like a candy bar. Go to builtbar.com and use promo code “LOCKED15,” and you'll get 15% off your next order.BetOnline AGThere is only 1 place that has you covered and 1 place we trust. Betonline.ag! Sign up today for a free account at betonline.ag and use that promocode: LOCKEDON for your 50% welcome bonus.Rock AutoAmazing selection. Reliably low prices. All the parts your car will ever need. Visit RockAuto.com and tell them Locked On sent you.Fully Loaded ChewFully Loaded Chew is offering LOCKED ON “TEAM” listeners a special offer – Rightnow you can try a can for just $1. Go to www.fullyloadedchew.com and use promo code: “LockedOn”FreshlyRight now, Freshly is offering our listeners $40 off your first two orders when you go to Freshly.com/LockedOn Learn more about your ad choices. Visit podcastchoices.com/adchoices

On today's Locked On Giants podcast, host Ben Kaspick talks about the San Francisco Giants' 3-0 win against the Marlins, in which Curt Casali collected his fifth straight shutout when he was the starting catcher. Casali also had a big two-run single in the first inning. The Giants improved to 12-7 with the win, and Casali became just the fifth catcher in MLB history to accomplish the feat. Aaron Sanchez pitched beautifully despite diminished velocity, and Gregory Santos made his major league debut out of the bullpen and was electric. He was added to the roster after Donovan Solano was placed on the IL. Matt Wisler, Tyler Rogers, and Jake McGee pitched scoreless frames as the Giants completed the shutout. Evan Longoria exited this game with left hamstring tightness.Listen to The Ultimate Mock Draft 2021 presented by Audacy and the Locked On Podcast Network. April 19th-26th. Follow the feed today!Support Us By Supporting Our Sponsors! Built BarBuilt Bar is a protein bar that tastes like a candy bar. Go to builtbar.com and use promo code “LOCKED15,” and you'll get 15% off your next order.BetOnline AGThere is only 1 place that has you covered and 1 place we trust. Betonline.ag! Sign up today for a free account at betonline.ag and use that promocode: LOCKED15 for your 50% welcome bonus.Rock AutoAmazing selection. Reliably low prices. All the parts your car will ever need. Visit RockAuto.com and tell them Locked On sent you. Learn more about your ad choices. Visit podcastchoices.com/adchoices

FPC Executive Director Reed Luhtanen goes Off the Rails with Joe Casali from NEACH. They discuss the evolution of faster payments, potential threats to traditional financial payments from Fintech and banking as a service, and the GOAT status of one Tom Brady.

In our first episode of 2021, Cannabitch Jackie Bryant talks to Johnny Casali, a second-generation marijuana farmer from Huckleberry Hill Farms.

On today's Locked On Giants podcast, host Ben Kaspick breaks down the San Francsico Giants' signing of free-agent catcher Curt Casali to a one-year, $1.5M deal. Casali has been significantly above average against left-handed pitching in his major league career, and has been below-average against righties. He's considered a likeable guy and a strong clubhouse presence. He rates as an average or above-average pitch framer, and his poptimes are below average. With Casali now in the fold, the Giants now figure to boast enviable depth and flexibility at the catcher position as we enter the 2021 season. Buster Posey is still one of the best catchers in the game, Casali is a solid backup with an exploitable skill, Chadwick Tromp is young, intriguing, and has minor league options, and Joey Bart, the fourth catcher on the 40-man, is one of the top prospects in the game.Also discussed on today's show is the Giants' potential pursuit of Japanese star pitcher Tomoyuki Sugano, who must choose an MLB team to sign with or return to Japan, by this Thursday. A decision, however, is expected as soon as today, and the Giants are reportedly among the interested teams.Support Us By Supporting Our Sponsors! Built BarBuilt Bar is a protein bar that tastes like a candy bar. Go to builtbar.com and use promo code “LOCKEDON,” and you'll get 20% off your next order.BetOnline AGThere is only 1 place that has you covered and 1 place we trust. Betonline.ag! Sign up today for a free account at betonline.ag and use that promocode: LOCKEDON for your 50% welcome bonus. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Thank you all, so much for the feedback on the series of The Women's Yoga & Healing Retreat. Today is part 3. If you missed the first two, feel free to go back and listen. In this episode I had the honor of speaking with Donna Casali, who was a guest on retreat. Donna and I have known each other for 10 years. We met through her attending my yoga classes, as well as collaborating together on different events. Donna shares her take-aways as well as part of the day and why someone would attend a retreat. After, Donna and I speak I included the end of our yoga class from that day. It is a small section which speaks of the 4 elements (water, air, fire and earth) and the 4 directions. Feel free to let me know what you thought about the show use #TinasRetreat for Instagram and FaceBook. Speaking about retreats. I have the honor of attending Katie Krimitsos Biz Women Rock Retreat in Orlando Florida. December 1-3. I will be up-leveling my business as well as sharing Reiki Treatments, Yoga and Meditation to the guests. Feel free to join me and Katie, to up-level your biz in 2018 Heres the link:http://bizwomenrock.com/retreat Do the holidays have you dressed and overwhelmed? The month of December on the podcast will be. Meditation Moments. Each week there will be a new 10 minute meditation for you to stay stress free and calm. Stay tuned Many Blessings~Tina